News & Updates

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

09 Apr 2021 by

A regimen comprising enzalutamide and androgen deprivation therapy (ADT) led to better outcomes compared with a bicalutamide-ADT regimen in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC), particularly in Black men, a phase II study suggests.

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

09 Apr 2021

New oral TRT exhibits favourable safety, efficacy for hypogonadal men

07 Apr 2021 by

A novel oral testosterone replacement therapy (TRT*) formulation – testosterone undecanoate (TU) – showed favourable safety and efficacy as long-term treatment for men with low testosterone levels, according to the extension phase results of a study presented at ENDO 2021.

New oral TRT exhibits favourable safety, efficacy for hypogonadal men

07 Apr 2021

Risk factors for hospital readmission in survivors of complicated UTI

03 Apr 2021

Survivors of complicated urinary tract infections (cUTI) are commonly readmitted for recurrent UTI, usually related to other medical conditions that require urinary interventions, a recent study has found.

Risk factors for hospital readmission in survivors of complicated UTI

03 Apr 2021

Original New Drug Application Approvals by US FDA (16 - 31 March 2021)

01 Apr 2021

New drug applications approved by US FDA as of 16-31 March 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 March 2021)

01 Apr 2021

Cabozantinib improves PFS, response in metastatic papillary RCC

23 Mar 2021 by

In patients with metastatic papillary renal cell carcinoma (PRCC), cabozantinib led to greater progression-free survival (PFS) and overall response rate (ORR) than sunitinib, results of the phase II SWOG 1500 study showed.

Cabozantinib improves PFS, response in metastatic papillary RCC

23 Mar 2021

Bipolar radiofrequency device boasts efficacy in prostate cancer treatment

22 Mar 2021

Focal therapy of significant localized prostate cancer associated with a magnetic resonance imaging (MRI) lesion using bipolar radiofrequency appears effective in ablating cancer, with low rates of genitourinary and rectal side effects, according to a study.

Bipolar radiofrequency device boasts efficacy in prostate cancer treatment

22 Mar 2021

MRI improves prognostication of prostate cancer metastases, death

21 Mar 2021

An association exists between magnetic resonance imaging (MRI) findings of localized prostate cancer and clinically relevant long-term oncologic outcomes, a study has found.

MRI improves prognostication of prostate cancer metastases, death

21 Mar 2021

What is the best strategy for erectile function recovery after radical prostatectomy?

20 Mar 2021

Treatment with 100-mg sildenafil appears to be the best strategy to improve erectile function recovery rates after radical prostatectomy, suggests a study. However, the on-demand dose of phosphodiesterase-5 (PDE5) inhibitors does not appear to be any better than placebo and must therefore not be considered as a penile rehabilitation strategy.

What is the best strategy for erectile function recovery after radical prostatectomy?

20 Mar 2021

No sexual, general quality of life impairment in long-term prostate cancer survivors

20 Mar 2021

Prostate cancer seems to have no long-term adverse effects on survivors’ sexual, genitourinary, and general quality of life, a recent study has found.

No sexual, general quality of life impairment in long-term prostate cancer survivors

20 Mar 2021

Novel tomato-based supplement shows potential for BPH treatment

17 Mar 2021 by

Consumption of a newly developed whole tomato‑based food supplement* (WTFS) led to improvements in lower urinary tract symptoms** (LUTS) and quality of life (QoL) in men with benign prostatic hyperplasia (BPH), a phase II Italian study has shown.

Novel tomato-based supplement shows potential for BPH treatment

17 Mar 2021

News & Updates

Filter by Specialty:

Specialty:

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

Enzalutamide tied to better outcomes than bicalutamide in mHSPC

New oral TRT exhibits favourable safety, efficacy for hypogonadal men

New oral TRT exhibits favourable safety, efficacy for hypogonadal men

Risk factors for hospital readmission in survivors of complicated UTI

Risk factors for hospital readmission in survivors of complicated UTI

Original New Drug Application Approvals by US FDA (16 - 31 March 2021)

Original New Drug Application Approvals by US FDA (16 - 31 March 2021)

Cabozantinib improves PFS, response in metastatic papillary RCC

Cabozantinib improves PFS, response in metastatic papillary RCC

Bipolar radiofrequency device boasts efficacy in prostate cancer treatment

Bipolar radiofrequency device boasts efficacy in prostate cancer treatment

MRI improves prognostication of prostate cancer metastases, death

MRI improves prognostication of prostate cancer metastases, death

What is the best strategy for erectile function recovery after radical prostatectomy?

What is the best strategy for erectile function recovery after radical prostatectomy?

No sexual, general quality of life impairment in long-term prostate cancer survivors

No sexual, general quality of life impairment in long-term prostate cancer survivors

Novel tomato-based supplement shows potential for BPH treatment

Novel tomato-based supplement shows potential for BPH treatment